You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
SBC: BIOVINC, LLC Topic: NIDCR
DESCRIPTION provided by applicant Infectious bone disease is a major cause of morbidity and mortality worldwide Successful treatment often requires surgical intervention with longer term antibiotic therapy Bacterial biofilm pathogens are associated with most osseous infections and represent a major target of therapy The biofilm pathogens associated with chronic bone infections bind to and co ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: VLP BIOTECH, INC. Topic: NIAID
DESCRIPTION provided by applicant Overall Staphylococcus aureus is a gram positive bacteria which possesses a multitude of virulence factors It is a frequent and severe pathogen in hospitals and of increasing concern in the community where it results in severe skin infections pneumonia bacterial endocarditis and sepsis A significant proportion of these infections are the result of methici ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: POLARONYX INC Topic: DHP15B002
Based on our success in developing the world first commercial high energy femtosecond fiber laser system and our leading proprietary technology development in ultrashort pulsed fiber laser material processing, PolarOnyx proposes, for the first time, a compact high energy fiber laser based smart wound healing tool to meet with the requirement of this DHP solicitation. It includes a high energy fs f ...STTR Phase I 2016 Department of DefenseDefense Health Agency
SBC: VIROGENOMICS BIODEVELOPMENT INC Topic: NIAID
DESCRIPTION provided by applicant Our laboratory discovered and is developing partial p MHC class II constructs pMHC as a possible immunotherapy for multiple sclerosis MS pMHC containing the extracellular domains of the MS risk factor HLA DR linked covalently to the encephalitogenic peptide of myelin oligodendrocyte glycoprotein pDR MOG can reverse CNS inflammation and ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: APPLIED STEMCELL, INC. Topic: 200
DESCRIPTION provided by applicant Gene correction therapy is one of the most important application directions in regenerative medicine Scientists are exploring various approaches to introduce targeted mutations corrections to pluripotent stem cells PSCs to establish disease models and or to develop therapeutic agents Emerging technologies such as Zinc Finger Nucleases ZFNs Transcription ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: DESIGNMEDIX, INC. Topic: R
DESCRIPTION provided by applicant Trichomonas vaginalis is the causative agent of the most common non viral sexually transmitted infection with million new cases reported annually in the world and million cases in the U S In addition to infections of the urogenital tract trichomoniasis increases the risk of adverse pregnancy outcomes and HIV transmission and increases the incidence ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: NeuroSigma, Inc. Topic: 101
DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: Zetroz Systems LLC Topic: A14AT016
Ultrasound is a therapeutic modality which has been used clinically for 60 years, but has been limited in practice by the complexity of the technology. Recent research has allowed for the development of a portable, wearable, long duration, low intensity therapeutic ultrasound system. The system is powered by battery, and can be applied by a user to deliver upSTTR Phase II 2016 Department of DefenseDefense Health Agency
SBC: L2 DIAGNOSTICS LLC Topic: 102
DESCRIPTION provided by applicant Hepatocellular carcinoma HCC is the most prevalent cancer in human population and will lead to over deaths in the United States this year alone However the molecular mechanisms driving hepatocellular carcinoma HCC growth and metastasis remain elusive and there is a huge unmet medical need to find new therapeutic targets We performed an unbiased ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: VIROGENICS, INC. Topic: NIAID
DESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health